We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
-2.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.7B
AUM Growth
-$733M
(-6.4%)
Cap. Flow
+$511M
Cap. Flow
% of AUM
4.78%
Top 10 Holdings %
Top 10 Hldgs %
33.24%
Holding
188
New
39
Increased
39
Reduced
24
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$452M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$186M |
| 3 |
CMMB
Chemomab Therapeutics
CMMB
|
+$128M |
| 4 |
Haemonetics
HAE
|
+$105M |
| 5 |
Disc Medicine
IRON
|
+$86.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prelude Therapeutics
PRLD
|
+$369M |
| 2 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
+$319M |
| 3 |
Pfizer
PFE
|
+$133M |
| 4 |
Biogen
BIIB
|
+$121M |
| 5 |
Centene
CNC
|
+$120M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.88% |
| 2 | Technology | 0.12% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Cartesian Therapeutics
RNAC
$216M
| $1.53M | 0.01% |
11,306
-6,666
| -37% | -$828K |
|
152
PUT
CEL-SCI Corp
CVM
$20.3M
| $1.52M | 0.01% |
+3,333
| New | +$1.82M |
|
|
MAPSW
153
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
| $1.06M | 0.01% |
+150,200
| New | +$1.23M |
|
|
NBP
154
NovaBridge Biosciences American Depositary Shares
NBP
$190M
| $900K | 0.01% |
18,565
-587,505
| -97% | -$31.9M |
|
155
Nautilus Biotechnolgy
NAUT
$142M
| $680K | 0.01% |
+49,375
| New | +$684K |
|
|
PPBT
156
Purple Biotech
PPBT
$1.3M
| $130K | ﹤0.01% |
157
-1,574
| -91% | -$1.47M |
|
|
TRIL
157
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
| $18K | ﹤0.01% |
+1,700
| New | +$21K |
|
158
Acadia Pharmaceuticals
ACAD
$4.46B
| – | – |
-265,772
| Closed | -$14.2M |
|
159
Acadia Healthcare
ACHC
$2.6B
| – | – |
-1,035,160
| Closed | -$52M |
|
160
Agios Pharmaceuticals
AGIO
$2.08B
| – | – |
-2,207,321
| Closed | -$95.6M |
|
161
Alcon
ALC
$34B
| – | – |
-351,380
| Closed | -$23.4M |
|
162
AtriCure
ATRC
$2.03B
| – | – |
-1,228,189
| Closed | -$68.4M |
|
|
163
Centene
CNC
$31.1B
| – | – |
-1,993,700
| Closed | -$120M |
|
164
Cogent Biosciences
COGT
$6.66B
| – | – |
-655,000
| Closed | -$7.36M |
|
165
eHealth
EHTH
$42.2M
| – | – |
-844,046
| Closed | -$59.6M |
|
166
Eledon Pharmaceuticals
ELDN
$259M
| – | – |
-73,650
| Closed | -$1.1M |
|
|
EPIX
167
DELISTED
ESSA Pharma
EPIX
| – | – |
-460,500
| Closed | -$5.49M |
|
168
4D Molecular Therapeutics
FDMT
$495M
| – | – |
-125,000
| Closed | -$5.18M |
|
169
Heron Therapeutics
HRTX
$92.4M
| – | – |
-1,191,846
| Closed | -$25.2M |
|
|
INZY
170
DELISTED
Inozyme Pharma
INZY
| – | – |
-400,400
| Closed | -$8.26M |
|
171
908 Devices
MASS
$312M
| – | – |
-40,000
| Closed | -$2.28M |
|
172
Outset Medical
OM
$86.8M
| – | – |
-8,333
| Closed | -$7.11M |
|
|
173
Pfizer
PFE
$144B
| – | – |
-3,616,600
| Closed | -$133M |
|
174
Praxis Precision Medicines
PRAX
$8.13B
| – | – |
-17,040
| Closed | -$14.1M |
|
175
Prothena Corp
PRTA
$442M
| – | – |
-1,797,458
| Closed | -$21.6M |
|
Similar funds
HSA
NL
BPWM
LFG
JIM
CTC
PAMP
SGM
OrbiMed's Q1 2021 Portfolio in Review
As of Q1 2021, OrbiMed held 188 positions worth $10.7B, down 6.4% from $11.4B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
OrbiMed deployed $511M of net new capital in Q1 2021, opening 39 new positions and adding to 39 existing holdings. Its largest new stake was Edgewise Therapeutics: 13,944,680 shares worth $453M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Prelude Therapeutics, an estimated $369M trimmed.
- OrbiMed's largest Q1 2021 buy was Edgewise Therapeutics: 13,944,680 shares worth $453M.
- OrbiMed added most to Merck in Q1 2021, an estimated $83M increase.
- OrbiMed's biggest Q1 2021 reduction was Prelude Therapeutics, cutting an estimated $369M.
- OrbiMed fully exited Prevail Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $319M.
- OrbiMed's ten largest holdings make up 33% of its $10.7B portfolio in Q1 2021.
- OrbiMed opened 39 new positions and closed 30 in Q1 2021.
- OrbiMed's portfolio value fell 6.4% quarter-over-quarter to $10.7B.
Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.